/ Cadila extends Gains Over USFDA Nod For Fingolimod Capsules ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 17 July 2017

Cadila Healthcare stock gained nearly 1% at Rs 535.40 per share on BSE as the pharma player on Friday has received a tentative approval from the USFDA to market Fingolimod Capsules, 0.5mg.

The drug is immunomodulating drug, mostly used for treating multiple sclerosis and will be produced a t group’s formulation manufacturing facility  at the Pharma SEZ in Ahmedabad.

Meanwhile on NSE the stock attracted a traded volume of 8,73,609 shares and a traded value of Rs 4,716.79 lakh.

 The company has a return on equity of 29.67%, the company has been maintaining a dividend payout of 21.79%.

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited etc.    

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717